Children (Nov 2022)

The Use of Psychotropic Medication in Pediatric Oncology for Acute Psychological and Psychiatric Problems: Balancing Risks and Benefits

  • Johanna M. C. Blom,
  • Elena Barisone,
  • Marina Bertolotti,
  • Daniela Caprino,
  • Monica Cellini,
  • Carlo Alfredo Clerici,
  • Chiara Colliva,
  • Cinzia Favara-Scacco,
  • Silvia Di Giuseppe,
  • Momcilo Jankovic,
  • Alessia Pancaldi,
  • Luca Pani,
  • Geraldina Poggi,
  • Veronica Rivi,
  • Fabio Tascedda,
  • Riccardo Torta,
  • Dorella Scarponi

DOI
https://doi.org/10.3390/children9121878
Journal volume & issue
Vol. 9, no. 12
p. 1878

Abstract

Read online

Severe acute behavioral and emotional problems represent one of the most serious treatment-related adverse effects for children and adolescents who have cancer. The critical and severe nature of these symptoms often makes necessary the use of psychotropic drugs. A working group composed of experts in multiple disciplines had the task of creating an agreement regarding a management plan for severe acute behavioral and emotional problems (SABEPs) in children and adolescents treated for cancer. To obtain global information on the use of psychotropic drugs in pediatric oncology, the working group first developed and mailed a 15-item questionnaire to many Italian pediatric oncology centers. Overall, an evident lack of knowledge and education regarding the use of psychotropic medications for the treatment of SABEPs was found. Thus, by referring to an adapted version of the Delphi method of consensus and standard methods for the elaboration of clinical questions (PICOs), the working group elaborated evidence-based recommendations for psychotropic drugs in the pediatric oncology setting. Furthermore, based on a thorough multivariate analysis of needs and difficulties, a comprehensive management flow was developed to optimize therapeutic interventions, which allows more accurate and efficient matching of the acute needs of patients while guiding treatment options.

Keywords